Novel Tracers for the Imaging of Cardiac Amyloidosis

Radionuclide scintigraphy with technetium-labeled bisphospho-nates has brought a paradigm shift in diagnosing cardiac amyloid-osis (CA), with transthyretin CA now being effectively diagnosed without the need for tissue biopsy. Yet, deficits remain, such as methods for the noninvasive diagnosis of light-chain CA, means to detect CA early, prognostication, monitoring, and therapy response assessment. To address these issues, there has been growing interest in the development and implementation of amyloid-specific radiotracers for PET. The aim of this review is to educate the reader on these novel imaging tracers. Though still investigational, these novel tracers-given their many advan-tages-are clearly the future of nuclear imaging in CA.